COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Ortonne, J. P. [1 ]
Feneron, D. [2 ]
Daures, J. P. [3 ]
Ollivier, A. L. [4 ]
Thiriet, C. [4 ]
Maurel, F. [2 ]
Le Pen, C. [5 ]
机构：
[1] Hop Archet 2, Nice, France
[2] IMS Hlth, Puteaux La Defense, France
[3] CHU Nimes, Nimes, France
[4] Wyeth Pharmaceut, Paris, France
[5] Univ Paris 09, Paris, France
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67017-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [31] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Reginald Villacorta
    Joel W. Hay
    Andrew Messali
    PharmacoEconomics, 2013, 31 : 823 - 839
  • [32] Efalizumab for patients with moderate to severe plaque psoriasis - A randomized controlled trial
    Gordon, KB
    Papp, KA
    Hamilton, TK
    Walicke, PA
    Dummer, W
    Li, N
    Bresnahan, BW
    Menter, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (23): : 3073 - 3080
  • [33] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [34] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [35] Cost effectiveness - Analysis of Therapy with Ustekinumab versus Etanercept in Patients with moderate to severe Plaque Psoriasis Based on the ACCEPT Study
    Augustin, M.
    Feldman, S.
    Wolbring, F.
    Szapary, P.
    Schenkel, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 191 - 191
  • [36] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
    Klimes, J.
    Mollon, P.
    Graham, C.
    Rajnoch, J.
    Dostal, F.
    Skalicky, D.
    Jordan, P.
    Depta, J.
    VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [37] Cost-effectiveness of tildrakizumab in U. S. patients with moderate-to-severe plaque psoriasis
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan
    Lowry, Simon
    Feldman, Steve R.
    Wu, Jashin J.
    Armstrong, April
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB39 - AB39
  • [38] Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
    Christopher Knight
    Josephine Mauskopf
    Mats Ekelund
    Amitabh Singh
    Shiyi Yang
    Robert Boggs
    The European Journal of Health Economics, 2012, 13 : 145 - 156
  • [39] Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
    Knight, Christopher
    Mauskopf, Josephine
    Ekelund, Mats
    Singh, Amitabh
    Yang, Shiyi
    Boggs, Robert
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (02): : 145 - 156
  • [40] Etanercept therapy for moderate to severe plaque psoriasis with involvement of the scalp
    Bagel, Jerry
    Kricorian, Gregory
    Klekotka, Paul
    Tyring, Stephen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB150 - AB150
12345